Trials / Conditions / Malignant Ovarian Endometrioid Tumor

Malignant Ovarian Endometrioid Tumor

4 registered clinical trials studyying Malignant Ovarian Endometrioid Tumor.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurr NCT04034927	National Cancer Institute (NCI)	Phase 2
Terminated	Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persisten NCT02569957	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 2
Completed	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cance NCT02020707	Mayo Clinic	Phase 1
Terminated	YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal NCT00899093	Gynecologic Oncology Group	—